These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23070000)

  • 1. Caspase-8 regulation of TRAIL-mediated cell death.
    Crowder RN; El-Deiry WS
    Exp Oncol; 2012 Oct; 34(3):160-4. PubMed ID: 23070000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.
    Belyanskaya LL; Ziogas A; Hopkins-Donaldson S; Kurtz S; Simon HU; Stahel R; Zangemeister-Wittke U
    Lung Cancer; 2008 Jun; 60(3):355-65. PubMed ID: 18093694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
    Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep 1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways.
    Lin FL; Hsu JL; Chou CH; Wu WJ; Chang CI; Liu HJ
    Eur J Pharmacol; 2011 Jan; 650(1):120-9. PubMed ID: 20951126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diallyl trisulfide sensitizes human melanoma cells to TRAIL-induced cell death by promoting endoplasmic reticulum-mediated apoptosis.
    Murai M; Inoue T; Suzuki-Karasaki M; Ochiai T; Ra C; Nishida S; Suzuki-Karasaki Y
    Int J Oncol; 2012 Dec; 41(6):2029-37. PubMed ID: 23064375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.
    VanOosten RL; Earel JK; Griffith TS
    Apoptosis; 2007 Mar; 12(3):561-71. PubMed ID: 17195089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of IG20 splice variants in TRAIL resistance.
    Prabhakar BS; Mulherkar N; Prasad KV
    Clin Cancer Res; 2008 Jan; 14(2):347-51. PubMed ID: 18223207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
    Vondálová Blanárová O; Jelínková I; Szöor A; Skender B; Soucek K; Horváth V; Vaculová A; Andera L; Sova P; Szöllosi J; Hofmanová J; Vereb G; Kozubík A
    Carcinogenesis; 2011 Jan; 32(1):42-51. PubMed ID: 21037225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling.
    Oh YT; Sun SY
    Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33810241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.
    Mazurek N; Byrd JC; Sun Y; Hafley M; Ramirez K; Burks J; Bresalier RS
    Cell Death Differ; 2012 Mar; 19(3):523-33. PubMed ID: 21941373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).
    Mellier G; Pervaiz S
    Free Radic Res; 2012 Aug; 46(8):996-1003. PubMed ID: 22559302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
    Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditionally replicating adenovirus combined with gene-targeted radiotherapy induces apoptosis via TRAIL death receptors in MDA-MB-231 cells.
    Wu JH; Wang HF; Wang ZC; Xu K; Qi YL; Li JH; Gong SL; Liu Y; Liu Y
    Mol Med Rep; 2013 Jul; 8(1):299-305. PubMed ID: 23708314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.